within Pharmacolibrary.Drugs.ATC.A;

model A10AE07
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.8,
    Cl             = 0.03 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 420 / 1000000,
    adminCount     = 1,
    Vd             = 0.011,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Insulin icodec is a long-acting, once-weekly basal insulin analogue developed for the treatment of diabetes mellitus in adults. Its ultra-long action profile allows for stable and sustained glucose-lowering effects, providing an alternative to daily basal insulins. It is approved for medical use in the European Union.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetic parameters reported for adult subjects with type 2 diabetes mellitus, both male and female, following subcutaneous administration.</p><h4>References</h4><ol><li><p>Nishimura, E, et al., &amp; Haahr, H (2021). Molecular and pharmacological characterization of insulin icodec: a new basal insulin analog designed for once-weekly dosing. <i>BMJ open diabetes research &amp; care</i> 9(1) –. DOI:<a href=&quot;https://doi.org/10.1136/bmjdrc-2021-002301&quot;>10.1136/bmjdrc-2021-002301</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34413118/&quot;>https://pubmed.ncbi.nlm.nih.gov/34413118</a></p></li><li><p>Pieber, TR, et al., &amp; Haahr, H (2023). Pharmacokinetic and pharmacodynamic properties of once-weekly insulin icodec in individuals with type 2 diabetes. <i>Diabetes, obesity &amp; metabolism</i> 25(12) 3716–3723. DOI:<a href=&quot;https://doi.org/10.1111/dom.15266&quot;>10.1111/dom.15266</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37694740/&quot;>https://pubmed.ncbi.nlm.nih.gov/37694740</a></p></li><li><p>Haahr, H, et al., &amp; Ignatenko, S (2024). The Effect of Various Degrees of Renal or Hepatic Impairment on the Pharmacokinetic Properties of Once-Weekly Insulin Icodec. <i>Clinical pharmacokinetics</i> 63(6) 819–830. DOI:<a href=&quot;https://doi.org/10.1007/s40262-024-01375-2&quot;>10.1007/s40262-024-01375-2</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38722461/&quot;>https://pubmed.ncbi.nlm.nih.gov/38722461</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end A10AE07;
